Frances Kittrell

Medicine · Health Sciences

34h-index4.2kcitations114works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(52), Cancer-related Molecular Pathways(50), Cancer Research and Treatments(23), Nutrition, Genetics, and Disease(11), Animal Genetics and Reproduction(9)

Publications114 total

Supplementary Materials 1 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Related Article from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Data from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
2023Open Access
Supplementary Materials 1 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Supplementary Materials 3 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Supplementary Materials 2 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Data from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Supplementary Materials 3 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Related Article from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
2023Open Access
Data from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Data from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
2023Open Access
Related Article from Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib
2023Open Access
Related Article from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Supplementary Materials 2 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model
2023Open Access
Data from Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer
2023Open Access
Supplementary Figure 4 from Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer
2023Open Access
Supplementary Figure 5 from Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer
2023Open Access
Supplementary Table 5 from Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer
2023Open Access
Supplementary Figure 3 from Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer
2023Open Access
Supplementary Figure 6 from Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Daniel Medina(28), Daniel Medina(19), Jeffrey M. Rosen(8), Fariba Behbod(5), Anne Shepard(5), David G. Edwards(4), Robert L. Ullrich(4), Maureen McCarthy(3), Carol J. Oborn(3), Yuhui Hu(3), C. Marcelo Aldaz(3), Heather L. Machado(3), Thenaa K. Said(3), Rachel L. Atkinson(2), Anna Tsimelzon(2), D. Craig Allred(2), D. Joseph Jerry(2), Rodolfo Laucirica(2), Ellen S. Dickinson(2), Janet S. Butel(2)